This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Aurora Cannabis (ACB) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued strength in Aurora Cannabis' (ACB) domestic-adult-recreational segment is expected to have driven Q1 sales.
Henry Schein (HSIC) Q3 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Strengthening demand in the global dental and medical markets drove Henry Schein's (HSIC) revenues in the third quarter.
Henry Schein (HSIC) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 17.02% and 8.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Earnings on Nov 2: IDXX, STE & More
by Urmimala Biswas
With the pandemic raging on, testing, vaccine and therapeutic makers are witnessing huge market adoption of their COVID-related support products in Q3.
Is a Surprise Coming for Henry Schein (HSIC) This Earnings Season?
by Zacks Equity Research
Henry Schein (HSIC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why the Earnings Surprise Streak Could Continue for Henry Schein (HSIC)
by Zacks Equity Research
Henry Schein (HSIC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
4 Medical Products Stocks Poised to Beat This Earnings Season
by Urmimala Biswas
Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.
BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences and Interventional segments is expected to have driven up Q4 sales.
What's in Store for Henry Schein (HSIC) in Q3 Earnings?
by Zacks Equity Research
Strengthening demand in the global dental and medical markets along with the recent investments are likely to have contributed to Henry Schein's (HSIC) Q3 performance.
Henry Schein (HSIC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SmileDirectClub (SDC) Introduces Two New Water Flossers
by Zacks Equity Research
SmileDirectClub (SDC) launched the new Large Tank and Compact Water Flossers, currently available at Shop.SmileDirectClub.com, Amazon, Walmart and Walmart.com.
Breast Health Sales to Drive Hologic's (HOLX) Q4 Earnings
by Zacks Equity Research
The acquisition of Biotheranostics and the launch of new software are expected to have contributed to Hologic's (HOLX) Breast Health arm performance in the fourth quarter.
Hologic (HOLX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Hologic's (HOLX) recent acquisitions and product launches are expected to contribute significantly to its fourth-quarter performance.
Here's Why You Should Hold on to Walgreens Boots (WBA) for Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA) given its better-than-expected fourth-quarter fiscal 2021 results and strategic alliances.
QIAGEN's (QGEN) New Manchester Facility to Fortify UK Foothold
by Zacks Equity Research
QIAGEN's (QGEN) new campus is expected to bring the benefits of transformational molecular diagnostics to Manchester and the global healthcare market.
Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Recovery in Clinical Diagnostics arm and strong growth in Droplet Digital PCR platform are expected to have contributed to Bio-Rad's (BIO) Q3 results.
Align Technology (ALGN) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Continued strong adoption of Invisalign Clear Aligners and iTero scanners is expected to contribute to Align Technology's (ALGN) third-quarter 2021 results.
Insulet's (PODD) Omnipod Sales Grow on New Product Upgrade
by Zacks Equity Research
Insulet (PODD) adds significant capacity in preparation for the Omnipod 5 launch in 2021.
Here's Why You Should Retain Bio-Rad (BIO) Stock For Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO) on solid international market performance and raised 2021 guidance.
QIAGEN (QGEN) New Launch to Aid Global TB Elimination Targets
by Zacks Equity Research
QIAGEN's (QGEN) QIAreach QuantiFERON-TB test is now accessible in high burden, low-resource regions.
ResMed (RMD) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strong customer demand and new product launches are likely to contribute to growth in the fiscal first quarter for ResMed (RMD).
Intuitive Surgical's (ISRG) Ion System Backed by Clinical Study
by Zacks Equity Research
Latest study results of Intuitive Surgical's (ISRG) Ion system indicate the potential for this technology to help safely biopsy small lung nodules.
Abbott's (ABT) Nutrition Arm in Focus on Real Madrid Alliance
by Zacks Equity Research
According to Abbott (ABT), the partnership is set to support education, sports and social welfare activities of at-risk children in 80 countries.
Here's Why You Should Retain Allscripts (MDRX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and various innovation milestones.
LHC Group (LHCG) Reports Impressive Preliminary Q3 Revenues
by Zacks Equity Research
Growth in LHC Group's (LHCG) revenues in the third quarter is likely to have been boosted by continued strength in its home health and hospice services.